IPOs

Medline sets stage for blockbuster US IPO with confidential filing
MSN/Reuters
Thu, 12/19/24 - 10:10 am
Medline
IPOs
medical supplies
Medtech
Invizyne’s IPO Aims to Bring Sustainable Biomanufacturing
Xtalks
Fri, 12/6/24 - 09:36 am
IPOs
Invizyne
Biomanufacturing
What can we learn from 2024’s biotech IPOs?
Fierce Biotech
Fri, 12/6/24 - 09:25 am
biotech
IPOs
Jupiter Neurosciences Makes Way in CNS Treatments with $11M IPO
Xtalks
Wed, 12/4/24 - 11:09 pm
Jupiter Neurosciences
CNS
IPOs
Medical supplier Medline aims to raise over $5 billion in 2025 IPO, sources say
Yahoo/Reuters
Fri, 11/22/24 - 11:18 am
Medtech
Medline
medical supplies
IPOs
Nasdaq debutante Septerna swells its IPO to $331m
Pharmaphorum
Thu, 10/31/24 - 09:16 am
Septerna
IPOs
GPCR drugmaker Septerna amasses $288M in IPO
BioPharma Dive
Fri, 10/25/24 - 10:59 am
Septerna
IPOs
GPCRs
Septerna plans $158M IPO to fund clinical readouts for GPCR pipeline
Fierce Biotech
Mon, 10/21/24 - 09:42 am
Septerna
IPOs
GPCRs
Upstream swells IPO to $255M as it prepares to join Nasdaq along with CAMP4
Fierce Biotech
Fri, 10/11/24 - 09:32 am
Upstream Bio
IPOs
CAMP4 Therapeutics
NASDAQ
CAMP4 is latest biotech to eye IPO, while Upstream spells out $182M plans
Fierce Biotech
Mon, 10/7/24 - 09:58 pm
CAMP4 Therapeutics
IPOs
Upstream Bio
RNA
Septerna files for IPO on strength of preclinical data, vision for expanding GPCR landscape
Fierce Biotech
Thu, 10/3/24 - 10:32 am
Septerna
IPOs
hypoparathyroidism
Zephyrm rides IPO updraft toward Hong Kong listing, seeking cash for phase 3 cell therapy trials
Fierce Biotech
Wed, 10/2/24 - 10:40 am
Zephyrm Bioscience
Hong Kong
IPOs
cell therapy
graft vs host disease
Respiratory disorder biotech Upstream Bio files for a $100 million IPO
Renaissance Capital
Wed, 09/18/24 - 11:10 pm
Upstream Bio
monoclonal antibodies
IPOs
Respiratory
Kairos goes public with $6M IPO to fund trials of lead cancer drug
Fierce Biotech
Tue, 09/17/24 - 10:54 am
ESMO
Kairos Therapeutics
IPOs
Three biotechs raise $700M in rare burst of IPO activity
BioPharma Dive
Fri, 09/13/24 - 09:22 am
IPOs
Bicara Therapeutics
Zenas BioPharma
MBX Biosciences
MBX aims for $136M IPO to take potential rival to Ascendis' Yorvipath into phase 3
Fierce Biotech
Mon, 09/9/24 - 07:10 pm
MBX Biosciences
IPOs
Yorvipath
Ascendis
Bicara Therapeutics aims for up to $828 mln valuation in U.S. IPO
Reuters
Fri, 09/6/24 - 10:55 am
Bicara Therapeutics
IPOs
cancer
Bristol-Myers Squibb-backed Zenas BioPharma seeks up to $689.7 mln valuation in US IPO
Reuters
Fri, 09/6/24 - 10:54 am
Zenas BioPharma
IPOs
Bristol Myers Squibb
obexelimab
BioAge files for IPO, plans pair of midstage obesity trials
Fierce Biotech
Wed, 09/4/24 - 11:40 am
BioAge Labs
IPOs
Eli Lilly
obesity
clinical trials
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
Motley Fool
Thu, 08/29/24 - 11:10 am
IPOs
Artiva
autoimmune diseases
cell therapy
AlloNK

Pages